The largest Chinese licensing deal behind Pfizer’s is Novartis’ partnership with Shanghai Argo Biopharma, worth potentially ...

Pfizer Inc. announced Monday it has secured exclusive global rights, excluding China, to 3SBio Inc.'s bispecific antibody ...

Pfizer faces several headwinds, including patent cliffs, regulatory risks, and a setback in obesity drug development. Click ...

The agreement comes three months after Pfizer inked a PD-1/VEGF partnership with Summit Therapeutics, leading BMO Capital ...

3SBio will grant Pfizer exclusive global rights, not including China, to develop, manufacture and commercialize SSGJ-707, a ...

Pfizer global commercial access partnerships director. Addressing challenges in prevention, personnel, facilities, and treatment can have a sweeping effect on the health of a population.

Pfizer (NYSE:PFE) is overhauling its cardiometabolic ... antagonist and pursuing external opportunities that could include partnerships or acquisitions. That strategic pivot comes as shares ...

we are committed to accelerating the availability of global innovations while fostering partnerships with governments, healthcare providers, and key stakeholders,” Serhat Yalcinkaya, Pfizer Gulf ...

With the company’s Q1 2025 results on Tuesday, Pfizer (NYSE:PFE) indicated plans to explore acquisitions or partnerships to add cardiometabolic assets, including weight loss therapies ...

Under the multi-year collaboration agreement, Guardant and Pfizer ... for its global clinical trials, which include China cohorts. In July 2022, Guardant announced a strategic partnership with ...

With the Trump administration imposing sweeping tariffs, fears of a global recession ... sales of Pfizer’s COVID products, Comirnaty and Paxlovid, which it developed in partnership with BioNTech ...